LG Chem, Ltd

Products

IVF-M HP™ Multidose™ Inj.

    • Product Name: IVF-M HP™ Multidose™ Inj.
    • Chemical Name (IUPAC): Menotrophin
    • CAS No.: 123401-00-9
    • Chemical Formula: C1007H1582N268O300S7
    • Form/Physical State: Lyophilized powder
    • Factroy Site:
    • Price Inquiry: sales6@ascent-chem.com
    • Manufacturer: LG Chem, Ltd
    • CONTACT NOW
    VTB
    Specifications
    HS Code 645086
    Brand Name IVF-M HP™ Multidose™ Inj.
    Active Ingredients Human Menopausal Gonadotropin (hMG)
    Drug Class Gonadotropins
    Strength 75 IU/vial
    Administration Route Subcutaneous or Intramuscular injection
    Indication Infertility treatment, ovarian stimulation
    Dosage Form Powder for solution for injection
    Manufacturer Bharat Serums and Vaccines Limited
    Prescription Status Prescription only
    Package Type Multidose vial

    As an accredited IVF-M HP™ Multidose™ Inj. factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing IVF-M HP™ Multidose™ Inj. packaging contains 1200 IU powder in a sterile glass vial, with ampoules of solvent for reconstitution.
    Container Loading (20′ FCL) Container Loading (20′ FCL) for IVF-M HP™ Multidose™ Inj.: 75,000 vials per 20-foot container, securely packed for export.
    Shipping The shipping of *IVF-M HP™ Multidose™ Inj.* requires temperature-controlled conditions, typically between 2°C and 8°C, to maintain product stability. The package should be securely sealed, labeled as a pharmaceutical product, and handled according to regulatory guidelines for medicinal shipments. Prompt delivery ensures the medication's efficacy upon arrival.
    Storage **IVF-M HP™ Multidose™ Inj.** should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect the vial from light and keep it in the original packaging until use. Do not freeze. After reconstitution, use the solution within the period specified by the manufacturer and store according to instructions provided in the product leaflet.
    Shelf Life IVF-M HP™ Multidose™ Inj. has a shelf life of 24 months when stored below 25°C, protected from light.
    Application of IVF-M HP™ Multidose™ Inj.

    Applications of IVF-M HP™ Multidose™ Inj. in Industrial Manufacturing

    IVF-M HP™ Multidose™ Inj. serves as a pharmaceutical-grade follicle stimulating hormone (FSH), widely integrated in fertility treatment product manufacturing and allied pharmaceutical production. Our raw material meets rigorous quality and regulatory expectations, supporting several critical downstream processes in the life sciences sector. Below are the primary industrial applications with detailed technical guidance and compliance reference.

    1. Recombinant Gonadotropin Formulations for Assisted Reproductive Technology (ART) Pharmaceuticals

    Pharmaceutical manufacturers leverage this high-purity FSH source to develop controlled ovarian hyperstimulation drugs used in IVF protocols. Formulators must precisely calibrate each batch for biological activity and protein homogeneity, ensuring consistent bioassay results. Integration demands validated lyophilization and aseptic filling procedures to secure hormone stability through final vialization, maintaining GMP traceability at all stages of processing.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    2. Biopharmaceutical CDMO and Contract API Bulk Preparation

    CDMO clients employ the raw material for bulk FSH API downstream processing before fill-finish. This includes scale-up fermentation, purification, and stringent filter sterilization. The material is tailored for bulk transfer in multi-use containers, meeting barcoded traceability for batch reconciliation and CMO transparency, according to cGMP requirements for API supply chain integrity.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    3. Formulation of Personalized Reproductive Medicine Kits

    Manufacturers of patient-specific therapy kits utilize this raw material for custom dosing based on clinical test results. The process integrates variable FSH concentrations with injection device componentry, ensuring precise fill volumes and homogenous dispersion. Stringent in-process checks and device-chemical compatibility testing are performed according to contemporary regulatory frameworks for combination products.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    4. Production of Reference Standards for Laboratory and Quality Control

    Raw material is used by analytical laboratories and QC units of pharmaceutical manufacturers to produce validated FSH reference standards. Laboratories calibrate and qualify each lot against international standards, ensuring consistent assay performance for potency, purity, and identity in release testing of finished pharmaceuticals.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    5. Development of Clinical Diagnostic Assay Kits

    Diagnostic device manufacturers employ the raw material as an essential calibrator and reagent control for FSH immunoassay kit production, facilitating accurate determination of hormone levels in clinical samples. Processes include conjugation to enzyme or fluorophore, kit assembly, and sealed packaging in humidity-controlled environments, in line with diagnostic industry regulations for quality and consistency.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    Free Quote

    Competitive IVF-M HP™ Multidose™ Inj. prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618018036652 or mail to sales6@ascent-chem.com.

    We will respond to you as soon as possible.

    Tel: +8618018036652

    Email: sales6@ascent-chem.com

    Inquiry

    Get Free Quote of LG Chem, Ltd

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    IVF-M HP™ Multidose™ Inj. – A Perspective from the Manufacturer

    Understanding IVF-M HP™ Multidose™ Inj. Straight from the Source

    It’s easy to talk about pharmaceuticals in broad, generalized terms, but we spend every day in direct contact with the science, the raw materials, the equipment, and – most importantly – the people who rely on our hormone preparations. IVF-M HP™ Multidose™ Inj. represents years of careful improvement and refinement. We have handled every stage, from sourcing highly purified human menopausal gonadotropin (hMG) to packaging in a way that fits real-world fertility protocols. Since each batch bears our signature, we take responsibility not just for compliance but for trust built in procedure rooms and patient homes worldwide.

    Forefront of Hormone Purification

    Every manufacturing run of IVF-M HP™ Multidose™ starts with our proprietary purification process. What looks like a clear vial hides a layered technical achievement: reducing proteins and contaminants to levels below current pharmacopoeial thresholds. Losing track of the small details isn’t possible when we see the direct impact of lot-to-lot consistency on patient outcomes. Lower impurity loads mean lower risk of immunogenic response, a point discussed in clinical safety reviews and in the questions that come from both clinicians and patients. While cheaper gonadotropins flood markets from various sources, clinics who have compared lots under the microscope acknowledge that the color, clarity, and solubility of IVF-M HP™ Multidose™ is a result of investment in chromatography columns and in-line analytics.

    Every vial of IVF-M HP™ Multidose™ carries measurable batch homogeneity, so patients do not see unexpected shifts in FSH or LH content from one vial to another. In open-label studies, fertility specialists have noted lower rates of lot-specific reactions. Even as new competitors have pushed for volume and cost-cutting, we stick to full-run purity analytics before vials leave our hands. No distributor or rep signs off on purity – that’s our responsibility as the manufacturer and a promise we keep with every lot sold.

    Reliable Dosing for a Multidose World

    IVF-M HP™ Multidose™ was designed with the full IVF protocol in mind. Patients and clinics demanded more flexibility, so we engineered a model that supports adjustable dosing schedules without repeated trips to the doctor. Every multidose vial contains highly purified hMG standardized for both FSH and LH content. The glass is made for repeated punctures, and the solvent is matched for pharmaceutical inactivity and ease of mixing.

    Many first-time patients worry about stability and sterility across several days of use. To that end, we run extended stability trials and track real-world handling data, not just out-of-box metrics. Our stoppers and flip-off caps pass industry testing, but our internal confidence comes from simulating worst-case scenarios, temperature spikes, and long multicenter IVF cycles. We see how much difference it makes when a vial drawn multiple times stays clear, particle-free, and maintains declared activity down to the last dose.

    Packaging That Speaks to Daily Challenges

    Feedback loops between our labs and IVF clinics drive how we package and deliver IVF-M HP™ Multidose™ Inj. We have fielded years’ worth of calls from nurses working late into the night, struggling to keep track of multiple brands and similar labels in busy fridges. IVF-M HP™ Multidose™ uses color-contrasted labeling, clear dose charts, and tamper-proof seals informed by these conversations. We print reconstitution instructions and dosing guides directly on secondary packaging, since we know leaflets can get misplaced. Barcodes include lot tracking, so no one has to cross-reference numbers during audits.

    Any decision made in our filling lines weighs how real people use the product under stress, not just how it looks in a catalog photo. We run pilot batches through actual IVF clinic settings prior to any broad-scale rollout. Sometimes this means smaller format changes go unnoticed by outsiders, but major changes—updates to snap caps, syringes calibrated for reduced dead space—come from the direct needs of users, made possible by our uniquely close feedback loop post-market.

    Comparisons and Key Differences in a Crowded Market

    Single-dose vials still have a place, particularly for streamlined cases, but demand for multidose solutions reflects realities in both private and public IVF centers. Some competitors produce high-volume vials, but without the internal stopper composition and antimicrobial standards needed for multidose reliability over several days, clinics report increased risk of contamination. Any manufacturer can claim multidose on a label, but supporting that claim means blending pharmaceutical-grade excipients, choosing vial glass that minimizes particulate risk, and packaging kits for safe repeated use.

    Competitor products using older extraction and purification methods often carry higher protein impurities and batch-to-batch variation in activity units. We use high-resolution chromatography, bioassays, and mass spectrometry not as marketing points but as requirements built into our GMP protocols. Each improvement answers real clinical outcomes – fewer injection site reactions, predictable ovarian response rates, and a reduced burden for pharmacy staff handling logbooks and returns. Other brands sometimes cut corners on lyophilization—slower dissolution, incomplete resuspension, or visible particles end up as clinic complaints. By controlling freeze-drying temperature ramps in our own cleanrooms, we consistently deliver a crystal-clear solution with rapid reconstitution.

    Daily Administration – Real-World Feedback Shaping Every Batch

    We build protocols around the kind of feedback only manufacturers hear: nurses mentioning stoppers that reseal poorly, pharmacists encountering variable dissolution times, and patients wanting better mixing instructions after hours. Whiteboards in our facility fill with direct quotes from sites across three continents. Dosing regimens for IVF-M HP™ Multidose™ adapt to physician preference, but the underlying consistency of FSH and LH units is something a distributor cannot deliver. Each batch runs through a proprietary activity assay, beyond what compliance requires, backed by side-by-side comparisons in collaboration with our partner clinics.

    We choose diluent with zero pyrogenicity risk, prescreened by testing panels for mimicry of real-world settings—refrigerator to room temp, morning to midnight. We also know patients must draw multiple doses over 7 to 10 days, prompting us to use high-density type I glass and stoppers with minimal coring rates, validated in daily practice audits. Not every manufacturer maintains this rigor, especially as cost pressures increase.

    Continuous Monitoring and Post-Market Commitment

    No launch of IVF-M HP™ Multidose™ happens in isolation. We trace and record every vial distributed, working with field teams to gather reports—not just adverse events, but details down to ease-of-use and patient satisfaction. Data from these follow-ups inform our tweaks: tuning the cap torque so fewer lids break in pharmacy prep; adjusting the pore size of reconstitution filters when clinics report minor blockages.

    A manufacturer’s job goes past initial QA checkpoints. Several international IVF clinics have signed up for our voluntary tracking program, feeding us incident reports that we audit every quarter. Our in-house statisticians review not just event outliers but every routine mixing or dosing comment, so patterns spot potential product improvements or early warning issues. This post-market vigilance, rooted in the reality of daily use, marks the distinction between a manufacturer maintaining real engagement and a logistic middleman selling cartons.

    The Human Side of Product Consistency

    Real people sit at the center of every lot we fill and ship. We have watched patients in training rooms learning self-injection, anxious but hopeful. We know each failed batch means not just financial loss but real consequences for couples investing everything in a single IVF cycle. This responsibility shapes how we run batch release analytics, document every fill volume, and respond to provider feedback.

    The consistency of IVF-M HP™ Multidose™ Inj. isn’t an accident. We maintain full control from starting material screening through final distribution. All raw materials undergo in-house audits beyond required standards, using cross-checked suppliers and regular test runs. Personnel who prepare culture media, run lyophilization, and seal vials participate in continuous professional development—our staff turnover rate sits significantly lower than sector norms, helping retain technical skill and experience.

    Supporting the Clinical Environment

    Clinic workflow stands or falls on the reliability of injected products. Quick withdrawal, low clogging rates, and reliable dose marking reduce mistakes and time spent on troubleshooting. IVF-M HP™ Multidose™ integrates with clinic flowsheets, backed by compatibility trials with major logging software and barcoding systems. We coordinate closely with large-scale pharmacy chains and hospital-based clinics to ensure our code numbers and dose metrics are automatically uploaded, cutting down on manual transcription and audit errors.

    We often get direct calls from clinical pharmacists and nurse managers. These conversations push us to refine not just labeling or vial seals, but also the clarity of mixing instructions, the durability of packaging during freight, and the addition of tamper-evidence bands. Changes are incremental, built on hundreds of hours of field data. Some improvements appear minor—a more resilient plunger, an instruction pictogram placed over a seam—but each one arises from our daily commitment as a manufacturer to the practical realities that clinics and patients encounter.

    Patient Experience Shapes Ongoing Innovation

    Patients remember their fertility journey in details: the temperature of the injection, the clarity of instructions, the confidence they gain in mixing and dosing. IVF-M HP™ Multidose™ Inj. is built not just for pharmacological performance but for comfort and usability. We work directly with patient advocacy groups, collecting stories and concerns, mapping these to every run. This feedback loop keeps us nimble, focused on comfort and simplicity in settings as diverse as major city fertility centers and rural practices.

    Reconstitution ease, low agitation requirement, and stability post-mixing come together in a multidose format patients actually use as prescribed. Missing or mistaken doses have real stakes, both financially and emotionally, and we bear this in mind at every production and quality checkpoint.

    Regulatory Engagement Born of Daily Practice

    Rather than seeing regulatory compliance as a hurdle, we view it as a shared framework to ensure patient safety. We work directly with auditors from global health authorities during every periodic inspection. Beyond documentation, inspectors tour our cleanrooms, verify our in-process controls, and review the data we collect on reconstitution rates, particulate levels, and dose accuracy across real-world cycles. Evidence of each process adjustment goes directly into annual reports, not as box-ticking but as part of ongoing dialogue about safety and performance.

    Our regulatory team also participates in collaborative research, sharing findings on batch outlier rates, new excipient performance, and stability curves with professional societies and regulatory science workshops. As debates about biosimilar gonadotropins intensify, we field requests for data transparency and respond directly with validated summaries, underlining where our lot data supports confidence among clinicians and patients choosing IVF-M HP™ Multidose™.

    The Manufacturer’s Promise

    No middleman stands between us and the clinics, the nurses, and the patients. We see every filled vial as a reflection of our drive for consistency and care. IVF-M HP™ Multidose™ Inj. is more than an item on a shelf. Its purity, repeat-use reliability, and packaging result from direct, daily engagement with the demands and challenges of fertility medicine.

    Working at this level means we celebrate not only production milestones and regulatory approvals, but each success story from a clinic or patient. Every feedback loop, process audit, or vial-of-the-day test connects our engineers, pharmacists, and quality staff with real-world outcomes. By keeping production in our own control, listening carefully to direct feedback, and refusing to compromise under commercial pressure, we deliver not a commodity but a proven partner in the IVF process.

    Building Toward the Future

    Years spent refining IVF-M HP™ Multidose™ Inj. have given us insight into both clinical success and everyday user satisfaction. As technology moves forward, we continue investing in research partnerships and real-world testing, keeping future-ready solutions closely tied to the present needs of patients and providers.

    Every advancement in lot testing, environmental monitoring, or materials science makes its way into our processes after careful vetting and user consultation. This hands-on, patient-driven approach to manufacturing stands at the heart of everything we do, setting IVF-M HP™ Multidose™ Inj. apart, batch after batch, for clinics and families working toward new beginnings.